MELISSA EIGENBRODE: Open Payments
NPI 1740784180 · EASTON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,500 in 63 payments from 25 companies in 2025. Trend: 2023 $963 · 2024 $2,185 · 2025 $1,500
Food & beverage: $1,500
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 11 | $317 |
| Ardelyx, Inc. | 3 | $144 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $135 |
| ABBVIE INC. | 6 | $117 |
| Intercept Pharmaceuticals, Inc. | 4 | $93 |
| AstraZeneca Pharmaceuticals LP | 4 | $82 |
| QOL Medical, LLC | 3 | $78 |
| Madrigal Pharmaceuticals | 3 | $61 |
| GENZYME CORPORATION | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
Products named: TREMFYA, IBSRELA, XIFAXAN, OCALIVA, DUPIXENT, Sucraid, REZDIFFRA, ENTYVIO.
Industry payments across MD — which companies pay providers there.
